AlzeCure Pharma AB (publ)

OM:ALZCUR Stock Report

Market Cap: SEK 215.4m

AlzeCure Pharma Future Growth

Future criteria checks 5/6

AlzeCure Pharma is forecast to grow earnings and revenue by 90.1% and 103% per annum respectively.

Key information

90.1%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth50.3%
Revenue growth rate103.0%
Future return on equityn/a
Analyst coverage

Low

Last updated08 May 2025

Recent future growth updates

Recent updates

We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth

Dec 02
We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth

Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth

Jul 20
Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth

Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?

Oct 12
Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Jan 03
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Jul 12
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Mar 28
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

Feb 03
Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Dec 13
We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Earnings and Revenue Growth Forecasts

OM:ALZCUR - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027333260N/A2601
12/31/202613-75N/A-751
12/31/20256119N/A191
3/31/2025N/A-36-36-36N/A
12/31/2024N/A-35-35-35N/A
9/30/2024N/A-36-36-36N/A
6/30/2024N/A-36-35-35N/A
3/31/2024N/A-37-35-35N/A
12/31/2023N/A-3733N/A
9/30/2023N/A-38-40-40N/A
6/30/2023N/A-42-47-47N/A
3/31/2023N/A-53-14-14N/A
12/31/2022N/A-56-100-100N/A
9/30/2022N/A-68-70-70N/A
6/30/2022N/A-73-70-70N/A
3/31/2022N/A-67-110-110N/A
12/31/2021N/A-78-71-71N/A
9/30/2021N/A-73-70-70N/A
6/30/2021N/A-78-75-75N/A
3/31/2021N/A-81-78-78N/A
12/31/2020N/A-71-70-70N/A
9/30/2020N/A-69-64-63N/A
6/30/2020N/A-61-57-56N/A
3/31/2020N/A-53-50-49N/A
12/31/2019N/A-51-52-50N/A
9/30/2019N/A-48-50-49N/A
6/30/2019-2-40-44-42N/A
3/31/2019-1-38-40-39N/A
12/31/2018N/A-36N/A-36N/A
9/30/20181-28N/A-29N/A
12/31/20171-10N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALZCUR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.3%).

Earnings vs Market: ALZCUR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALZCUR is expected to become profitable in the next 3 years.

Revenue vs Market: ALZCUR's revenue (103% per year) is forecast to grow faster than the Swedish market (4.2% per year).

High Growth Revenue: ALZCUR's revenue (103% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALZCUR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 20:34
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AlzeCure Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonas PeciulisEdison Investment Research
Fredrik ThorRedeye
Felicia RittemarVator Securities AB